WHAT IS CLAIMED IS:

1		1.	A method for preventing or treating an autoimmune disease in a
2	subject, the m	ethod o	comprising the step of administering to the subject a therapeutically
3	effective amo	unt of a	an Activity Dependent Neurotrophic Factor (ADNF) polypeptide,
4	wherein the A	DNF p	polypeptide is a member selected from the group consisting of:
5		(a) an	ADNF I polypeptide comprising an active core site having the following
6	amino acid se	quence	
7		Ser-A	.la-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1);
8		(b) an	ADNF III polypeptide comprising an active core site having the
9	following ami	no acio	i sequence:
10		Asn-A	Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2); and
11		(c) a r	mixture of the ADNF I polypeptide of part (a) and the ADNF III
12	polypeptide of	f part (b).
1		2.	The method of claim 1, wherein the ADNF polypeptide is a member
2	calacted from		oup consisting of a full length ADNF I polypeptide, a full length ADNF
3		•	a mixture of a full length ADNF I polypeptide and a full length ADNF
4	III polypeptid	-	a mixture of a run lengui 715141. I porypopulae and a run longui 715141
4	iii porypeptid	C .	
1		3.	The method of claim 1, wherein the ADNF polypeptide is an ADNF I
2	polypeptide.		
1		4	The mostle defection 2 subarrain the active core gite of the ADNE I
1	1 (1)	4.	The method of claim 3, wherein the active core site of the ADNF I
2	polypeptide co	ompris	es at least one D-amino acid.
1		5.	The method of claim 3, wherein the active core site of the ADNF I
2	polypeptide co	ompris	es all D-amino acids.
1		6.	The method of claim 3, wherein the ADNF I polypeptide is Ser-Ala-
2	Leu-Leu-Arg-	Ser-Ile	e-Pro-Ala (SEQ ID NO:1).
1		7.	The method of claim 3, wherein the ADNF I polypeptide is selected
2	from the grou	p consi	isting of:
3			-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:14);

- 4 Val-Glu-Gly-Ile-Val-Leu-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala
- 5 (SEQ ID NO:15);
- 6 Leu-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:16);
- 7 Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:17);
- 8 Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:18);
- 9 Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:19); and
- 10 Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1).
- 1 8. The method of claim 3, wherein the ADNF I polypeptide comprises up
- 2 to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active
- 3 core site.
- 1 9. The method of claim 1, wherein the ADNF polypeptide is an ADNF III
- 2 polypeptide.
- 1 10. The method of claim 9, wherein the ADNF polypeptide is a full length
- 2 ADNF III polypeptide.
- 1 The method of claim 9, wherein the ADNF III polypeptide is Asn-Ala-
- 2 Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:1).
- 1 12. The method of claim 9, wherein the active core site of the ADNF III
- 2 polypeptide comprises at least one D-amino acid.
- 1 13. The method of claim 9, wherein the active core site of the ADNF III
- 2 polypeptide comprises all D-amino acids.
- 1 14. The method of claim 9, wherein the ADNF III polypeptide is a
- 2 member selected from the group consisting of:
- 3 Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2);
- 4 Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:3);
- 5 Leu-Gly-Leu-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:4);
- 6 Ser-Val-Arg-Leu-Gly-Leu-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ
- 7 ID NO:5); and
- 8 Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:1).

1	15. The method of claim 9, wherein the ADNF III polypeptide comprises
2	up to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active
3	core site.
	16 The set of Collins to the sain at least one of the ADNE polymortides
1	16. The method of claim 1, wherein at least one of the ADNF polypeptides
2	is encoded by a nucleic acid that is administered to the subject.
1	17. The method of claim 1, wherein an ADNF I polypeptide of part (a) and
2	an ADNF III polypeptide of part (b) are administered to the subject.
1	18. The method of claim 17, wherein either or both active core sites of the
2	ADNF I polypeptide and the ADNF III polypeptide comprise at least one D-amino acid.
1	19. The method of claim 17, wherein either or both active core sites of the
2	ADNF I polypeptide and the ADNF III polypeptide comprise all D-amino acids.
	7.D.1.1 1 polypopilae and the 1.D.1.2 111 polypopilae complete and 1
1	20. The method of claim 17, wherein the ADNF I polypeptide is Ser-Ala-
2	Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1), and wherein the ADNF III polypeptide is
3	Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2).
1	21. The method of claim 17, wherein the ADNF I polypeptide is a member
2	selected from the group consisting of:
3	Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:14);
4	Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala
5	(SEQ ID NO:15);
6	Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:16);
7	Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:17);
8	Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:18);
9	Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:19); and
10	Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1); and
11	wherein the ADNF III polypeptide is selected from the group consisting of:
12	Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:20);
13	Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:21);
14	Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ ID NO:22);

.15	Ser-Val-Arg-Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-Gln-Ser (SEQ
16	ID NO:23); and
17	Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2).
1	22. The method of claim 17, wherein the ADNF I polypeptide comprises
2	up to about 20 amino acids at at least one of the N-terminus and the C-terminus of the active
3	core site of the ADNF I polypeptide, and wherein the ADNF III polypeptide comprises up to
4	about 20 amino acids at at least one of the N-terminus and the C-terminus of the active core
5	site of the ADNF III polypeptide.
1	23. The method of claim 1, wherein the subject has an autoimmune
2	disease.
1	24. The method of claim 1, wherein the ADNF polypeptide is administered
2	to prevent an autoimmune disease.
1	25. The method of claim 1, wherein the autoimmune disease is selected
	25. The method of claim 1, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome
2	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome
2	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens
2 3 4	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary
2 3 4 5	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves'
2 3 4 5 6	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves' disease/hyperthyroiditis, scleroderma, chronic idiopathic thrombocytopenic purpura, diabetic
2 3 4 5	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves'
2 3 4 5 6	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves' disease/hyperthyroiditis, scleroderma, chronic idiopathic thrombocytopenic purpura, diabetic
2 3 4 5 6 7	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves' disease/hyperthyroiditis, scleroderma, chronic idiopathic thrombocytopenic purpura, diabetic neuropathy and septic shock.
2 3 4 5 6 7	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves' disease/hyperthyroiditis, scleroderma, chronic idiopathic thrombocytopenic purpura, diabetic neuropathy and septic shock. 26. The method of claim 1, wherein the ADNF polypeptide is administered.
2 3 4 5 6 7 1 2	from the group consisting of multiple sclerosis, myasthenia gravis, Guillan-Barre syndrome (antiphospholipid syndrome), systemic lupus erytromatosis, Behcet's syndrome, Sjogrens syndrome, rheumatoid arthritis, Hashimoto's disease/hypothyroiditis, primary biliary cirrhosis, mixed connective tissue disease, chronic active hepatitis, Graves' disease/hyperthyroiditis, scleroderma, chronic idiopathic thrombocytopenic purpura, diabetic neuropathy and septic shock. 26. The method of claim 1, wherein the ADNF polypeptide is administered intranasally.